Industry Research Reports

Home > Reports > Pharma & Healthcare > Ischemic Heart Disease Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Ischemic Heart Disease Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Pharma & Healthcare

Published: 2024-01-24

Pages: 127 Pages

Report ld: 2331259

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

The global market for Ischemic Heart Disease Drugs was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Ischemic Heart Disease Drugs, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Ischemic Heart Disease Drugs by region & country, by Type, and by Application.

The Ischemic Heart Disease Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ischemic Heart Disease Drugs.

Market Segmentation

Report Metric
Details
Report Title
Ischemic Heart Disease Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Global Ischemic Heart Disease Drugs Companies Covered
AstraZeneca, Actelion, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Baxter, Eli Lilly and Company, Novartis, Pfizer, Sanofi
Global Ischemic Heart Disease Drugs Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Ischemic Heart Disease Drugs Market, Segment by Type
Angina Pectoris

Myocardial Infarction
Global Ischemic Heart Disease Drugs Market, Segment by Application
Anti-dyslipidemic Drugs

Calcium Channel Blockers

Beta-blockers

ACE Inhibitors

ARBs

Vasodilators

Antithrombotic Agents
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Ischemic Heart Disease Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Ischemic Heart Disease Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Ischemic Heart Disease Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

 1 Market Overview
    1.1 Ischemic Heart Disease Drugs Product Introduction
    1.2 Global Ischemic Heart Disease Drugs Market Size Forecast
        1.2.1 Global Ischemic Heart Disease Drugs Sales Value (2019-2030)
        1.2.2 Global Ischemic Heart Disease Drugs Sales Volume (2019-2030)
        1.2.3 Global Ischemic Heart Disease Drugs Sales Price (2019-2030)
    1.3 Ischemic Heart Disease Drugs Market Trends & Drivers
        1.3.1 Ischemic Heart Disease Drugs Industry Trends
        1.3.2 Ischemic Heart Disease Drugs Market Drivers & Opportunity
        1.3.3 Ischemic Heart Disease Drugs Market Challenges
        1.3.4 Ischemic Heart Disease Drugs Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Ischemic Heart Disease Drugs Players Revenue Ranking (2023)
    2.2 Global Ischemic Heart Disease Drugs Revenue by Company (2019-2024)
    2.3 Global Ischemic Heart Disease Drugs Players Sales Volume Ranking (2023)
    2.4 Global Ischemic Heart Disease Drugs Sales Volume by Company Players (2019-2024)
    2.5 Global Ischemic Heart Disease Drugs Average Price by Company (2019-2024)
    2.6 Key Manufacturers Ischemic Heart Disease Drugs Manufacturing Base Distribution and Headquarters
    2.7 Key Manufacturers Ischemic Heart Disease Drugs Product Offered
    2.8 Key Manufacturers Time to Begin Mass Production of Ischemic Heart Disease Drugs
    2.9 Ischemic Heart Disease Drugs Market Competitive Analysis
        2.9.1 Ischemic Heart Disease Drugs Market Concentration Rate (2019-2024)
        2.9.2 Global 5 and 10 Largest Manufacturers by Ischemic Heart Disease Drugs Revenue in 2023
        2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ischemic Heart Disease Drugs as of 2023)
    2.10 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Angina Pectoris
        3.1.2 Myocardial Infarction
    3.2 Global Ischemic Heart Disease Drugs Sales Value by Type
        3.2.1 Global Ischemic Heart Disease Drugs Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Ischemic Heart Disease Drugs Sales Value, by Type (2019-2030)
        3.2.3 Global Ischemic Heart Disease Drugs Sales Value, by Type (%) (2019-2030)
    3.3 Global Ischemic Heart Disease Drugs Sales Volume by Type
        3.3.1 Global Ischemic Heart Disease Drugs Sales Volume by Type (2019 VS 2023 VS 2030)
        3.3.2 Global Ischemic Heart Disease Drugs Sales Volume, by Type (2019-2030)
        3.3.3 Global Ischemic Heart Disease Drugs Sales Volume, by Type (%) (2019-2030)
    3.4 Global Ischemic Heart Disease Drugs Average Price by Type (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Anti-dyslipidemic Drugs
        4.1.2 Calcium Channel Blockers
        4.1.3 Beta-blockers
        4.1.4 ACE Inhibitors
        4.1.5 ARBs
        4.1.6 Vasodilators
        4.1.7 Antithrombotic Agents
    4.2 Global Ischemic Heart Disease Drugs Sales Value by Application
        4.2.1 Global Ischemic Heart Disease Drugs Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Ischemic Heart Disease Drugs Sales Value, by Application (2019-2030)
        4.2.3 Global Ischemic Heart Disease Drugs Sales Value, by Application (%) (2019-2030)
    4.3 Global Ischemic Heart Disease Drugs Sales Volume by Application
        4.3.1 Global Ischemic Heart Disease Drugs Sales Volume by Application (2019 VS 2023 VS 2030)
        4.3.2 Global Ischemic Heart Disease Drugs Sales Volume, by Application (2019-2030)
        4.3.3 Global Ischemic Heart Disease Drugs Sales Volume, by Application (%) (2019-2030)
    4.4 Global Ischemic Heart Disease Drugs Average Price by Application (2019-2030)

 5 Segmentation by Region
    5.1 Global Ischemic Heart Disease Drugs Sales Value by Region
        5.1.1 Global Ischemic Heart Disease Drugs Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Ischemic Heart Disease Drugs Sales Value by Region (2019-2024)
        5.1.3 Global Ischemic Heart Disease Drugs Sales Value by Region (2025-2030)
        5.1.4 Global Ischemic Heart Disease Drugs Sales Value by Region (%), (2019-2030)
    5.2 Global Ischemic Heart Disease Drugs Sales Volume by Region
        5.2.1 Global Ischemic Heart Disease Drugs Sales Volume by Region: 2019 VS 2023 VS 2030
        5.2.2 Global Ischemic Heart Disease Drugs Sales Volume by Region (2019-2024)
        5.2.3 Global Ischemic Heart Disease Drugs Sales Volume by Region (2025-2030)
        5.2.4 Global Ischemic Heart Disease Drugs Sales Volume by Region (%), (2019-2030)
    5.3 Global Ischemic Heart Disease Drugs Average Price by Region (2019-2030)
    5.4 North America
        5.4.1 North America Ischemic Heart Disease Drugs Sales Value, 2019-2030
        5.4.2 North America Ischemic Heart Disease Drugs Sales Value by Country (%), 2023 VS 2030
    5.5 Europe
        5.5.1 Europe Ischemic Heart Disease Drugs Sales Value, 2019-2030
        5.5.2 Europe Ischemic Heart Disease Drugs Sales Value by Country (%), 2023 VS 2030
    5.6 Asia Pacific
        5.6.1 Asia Pacific Ischemic Heart Disease Drugs Sales Value, 2019-2030
        5.6.2 Asia Pacific Ischemic Heart Disease Drugs Sales Value by Country (%), 2023 VS 2030
    5.7 South America
        5.7.1 South America Ischemic Heart Disease Drugs Sales Value, 2019-2030
        5.7.2 South America Ischemic Heart Disease Drugs Sales Value by Country (%), 2023 VS 2030
    5.8 Middle East & Africa
        5.8.1 Middle East & Africa Ischemic Heart Disease Drugs Sales Value, 2019-2030
        5.8.2 Middle East & Africa Ischemic Heart Disease Drugs Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Ischemic Heart Disease Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Ischemic Heart Disease Drugs Sales Value
        6.2.1 Key Countries/Regions Ischemic Heart Disease Drugs Sales Value, 2019-2030
        6.2.2 Key Countries/Regions Ischemic Heart Disease Drugs Sales Volume, 2019-2030
    6.3 United States
        6.3.1 United States Ischemic Heart Disease Drugs Sales Value, 2019-2030
        6.3.2 United States Ischemic Heart Disease Drugs Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Ischemic Heart Disease Drugs Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Ischemic Heart Disease Drugs Sales Value, 2019-2030
        6.4.2 Europe Ischemic Heart Disease Drugs Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Ischemic Heart Disease Drugs Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Ischemic Heart Disease Drugs Sales Value, 2019-2030
        6.5.2 China Ischemic Heart Disease Drugs Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Ischemic Heart Disease Drugs Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Ischemic Heart Disease Drugs Sales Value, 2019-2030
        6.6.2 Japan Ischemic Heart Disease Drugs Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Ischemic Heart Disease Drugs Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Ischemic Heart Disease Drugs Sales Value, 2019-2030
        6.7.2 South Korea Ischemic Heart Disease Drugs Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Ischemic Heart Disease Drugs Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Ischemic Heart Disease Drugs Sales Value, 2019-2030
        6.8.2 Southeast Asia Ischemic Heart Disease Drugs Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Ischemic Heart Disease Drugs Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Ischemic Heart Disease Drugs Sales Value, 2019-2030
        6.9.2 India Ischemic Heart Disease Drugs Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Ischemic Heart Disease Drugs Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 AstraZeneca
        7.1.1 AstraZeneca Company Information
        7.1.2 AstraZeneca Introduction and Business Overview
        7.1.3 AstraZeneca Ischemic Heart Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.1.4 AstraZeneca Ischemic Heart Disease Drugs Product Offerings
        7.1.5 AstraZeneca Recent Development
    7.2 Actelion
        7.2.1 Actelion Company Information
        7.2.2 Actelion Introduction and Business Overview
        7.2.3 Actelion Ischemic Heart Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.2.4 Actelion Ischemic Heart Disease Drugs Product Offerings
        7.2.5 Actelion Recent Development
    7.3 Bayer
        7.3.1 Bayer Company Information
        7.3.2 Bayer Introduction and Business Overview
        7.3.3 Bayer Ischemic Heart Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.3.4 Bayer Ischemic Heart Disease Drugs Product Offerings
        7.3.5 Bayer Recent Development
    7.4 Boehringer Ingelheim
        7.4.1 Boehringer Ingelheim Company Information
        7.4.2 Boehringer Ingelheim Introduction and Business Overview
        7.4.3 Boehringer Ingelheim Ischemic Heart Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.4.4 Boehringer Ingelheim Ischemic Heart Disease Drugs Product Offerings
        7.4.5 Boehringer Ingelheim Recent Development
    7.5 Bristol-Myers Squibb
        7.5.1 Bristol-Myers Squibb Company Information
        7.5.2 Bristol-Myers Squibb Introduction and Business Overview
        7.5.3 Bristol-Myers Squibb Ischemic Heart Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.5.4 Bristol-Myers Squibb Ischemic Heart Disease Drugs Product Offerings
        7.5.5 Bristol-Myers Squibb Recent Development
    7.6 Baxter
        7.6.1 Baxter Company Information
        7.6.2 Baxter Introduction and Business Overview
        7.6.3 Baxter Ischemic Heart Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.6.4 Baxter Ischemic Heart Disease Drugs Product Offerings
        7.6.5 Baxter Recent Development
    7.7 Eli Lilly and Company
        7.7.1 Eli Lilly and Company Company Information
        7.7.2 Eli Lilly and Company Introduction and Business Overview
        7.7.3 Eli Lilly and Company Ischemic Heart Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.7.4 Eli Lilly and Company Ischemic Heart Disease Drugs Product Offerings
        7.7.5 Eli Lilly and Company Recent Development
    7.8 Novartis
        7.8.1 Novartis Company Information
        7.8.2 Novartis Introduction and Business Overview
        7.8.3 Novartis Ischemic Heart Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.8.4 Novartis Ischemic Heart Disease Drugs Product Offerings
        7.8.5 Novartis Recent Development
    7.9 Pfizer
        7.9.1 Pfizer Company Information
        7.9.2 Pfizer Introduction and Business Overview
        7.9.3 Pfizer Ischemic Heart Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.9.4 Pfizer Ischemic Heart Disease Drugs Product Offerings
        7.9.5 Pfizer Recent Development
    7.10 Sanofi
        7.10.1 Sanofi Company Information
        7.10.2 Sanofi Introduction and Business Overview
        7.10.3 Sanofi Ischemic Heart Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.10.4 Sanofi Ischemic Heart Disease Drugs Product Offerings
        7.10.5 Sanofi Recent Development

 8 Industry Chain Analysis
    8.1 Ischemic Heart Disease Drugs Industrial Chain
    8.2 Ischemic Heart Disease Drugs Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Ischemic Heart Disease Drugs Sales Model
        8.5.2 Sales Channel
        8.5.3 Ischemic Heart Disease Drugs Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Ischemic Heart Disease Drugs Market Trends
    Table 2. Ischemic Heart Disease Drugs Market Drivers & Opportunity
    Table 3. Ischemic Heart Disease Drugs Market Challenges
    Table 4. Ischemic Heart Disease Drugs Market Restraints
    Table 5. Global Ischemic Heart Disease Drugs Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Ischemic Heart Disease Drugs Revenue Market Share by Company (2019-2024)
    Table 7. Global Ischemic Heart Disease Drugs Sales Volume by Company (2019-2024) & (K Units)
    Table 8. Global Ischemic Heart Disease Drugs Sales Volume Market Share by Company (2019-2024)
    Table 9. Global Market Ischemic Heart Disease Drugs Price by Company (2019-2024) & (USD/Unit)
    Table 10. Key Manufacturers Ischemic Heart Disease Drugs Manufacturing Base Distribution and Headquarters
    Table 11. Key Manufacturers Ischemic Heart Disease Drugs Product Type
    Table 12. Key Manufacturers Time to Begin Mass Production of Ischemic Heart Disease Drugs
    Table 13. Global Ischemic Heart Disease Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ischemic Heart Disease Drugs as of 2023)
    Table 15. Mergers & Acquisitions, Expansion Plans
    Table 16. Global Ischemic Heart Disease Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 17. Global Ischemic Heart Disease Drugs Sales Value by Type (2019-2024) & (US$ Million)
    Table 18. Global Ischemic Heart Disease Drugs Sales Value by Type (2025-2030) & (US$ Million)
    Table 19. Global Ischemic Heart Disease Drugs Sales Market Share in Value by Type (2019-2024) & (%)
    Table 20. Global Ischemic Heart Disease Drugs Sales Market Share in Value by Type (2025-2030) & (%)
    Table 21. Global Ischemic Heart Disease Drugs Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
    Table 22. Global Ischemic Heart Disease Drugs Sales Volume by Type (2019-2024) & (K Units)
    Table 23. Global Ischemic Heart Disease Drugs Sales Volume by Type (2025-2030) & (K Units)
    Table 24. Global Ischemic Heart Disease Drugs Sales Market Share in Volume by Type (2019-2024) & (%)
    Table 25. Global Ischemic Heart Disease Drugs Sales Market Share in Volume by Type (2025-2030) & (%)
    Table 26. Global Ischemic Heart Disease Drugs Price by Type (2019-2024) & (USD/Unit)
    Table 27. Global Ischemic Heart Disease Drugs Price by Type (2025-2030) & (USD/Unit)
    Table 28. Global Ischemic Heart Disease Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 29. Global Ischemic Heart Disease Drugs Sales Value by Application (2019-2024) & (US$ Million)
    Table 30. Global Ischemic Heart Disease Drugs Sales Value by Application (2025-2030) & (US$ Million)
    Table 31. Global Ischemic Heart Disease Drugs Sales Market Share in Value by Application (2019-2024) & (%)
    Table 32. Global Ischemic Heart Disease Drugs Sales Market Share in Value by Application (2025-2030) & (%)
    Table 33. Global Ischemic Heart Disease Drugs Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
    Table 34. Global Ischemic Heart Disease Drugs Sales Volume by Application (2019-2024) & (K Units)
    Table 35. Global Ischemic Heart Disease Drugs Sales Volume by Application (2025-2030) & (K Units)
    Table 36. Global Ischemic Heart Disease Drugs Sales Market Share in Volume by Application (2019-2024) & (%)
    Table 37. Global Ischemic Heart Disease Drugs Sales Market Share in Volume by Application (2025-2030) & (%)
    Table 38. Global Ischemic Heart Disease Drugs Price by Application (2019-2024) & (USD/Unit)
    Table 39. Global Ischemic Heart Disease Drugs Price by Application (2025-2030) & (USD/Unit)
    Table 40. Global Ischemic Heart Disease Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Global Ischemic Heart Disease Drugs Sales Value by Region (2019-2024) & (US$ Million)
    Table 42. Global Ischemic Heart Disease Drugs Sales Value by Region (2025-2030) & (US$ Million)
    Table 43. Global Ischemic Heart Disease Drugs Sales Value by Region (2019-2024) & (%)
    Table 44. Global Ischemic Heart Disease Drugs Sales Value by Region (2025-2030) & (%)
    Table 45. Global Ischemic Heart Disease Drugs Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
    Table 46. Global Ischemic Heart Disease Drugs Sales Volume by Region (2019-2024) & (K Units)
    Table 47. Global Ischemic Heart Disease Drugs Sales Volume by Region (2025-2030) & (K Units)
    Table 48. Global Ischemic Heart Disease Drugs Sales Volume by Region (2019-2024) & (%)
    Table 49. Global Ischemic Heart Disease Drugs Sales Volume by Region (2025-2030) & (%)
    Table 50. Global Ischemic Heart Disease Drugs Average Price by Region (2019-2024) & (USD/Unit)
    Table 51. Global Ischemic Heart Disease Drugs Average Price by Region (2025-2030) & (USD/Unit)
    Table 52. Key Countries/Regions Ischemic Heart Disease Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 53. Key Countries/Regions Ischemic Heart Disease Drugs Sales Value, (2019-2024) & (US$ Million)
    Table 54. Key Countries/Regions Ischemic Heart Disease Drugs Sales Value, (2025-2030) & (US$ Million)
    Table 55. Key Countries/Regions Ischemic Heart Disease Drugs Sales Volume, (2019-2024) & (K Units)
    Table 56. Key Countries/Regions Ischemic Heart Disease Drugs Sales Volume, (2025-2030) & (K Units)
    Table 57. AstraZeneca Company Information
    Table 58. AstraZeneca Introduction and Business Overview
    Table 59. AstraZeneca Ischemic Heart Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 60. AstraZeneca Ischemic Heart Disease Drugs Product Offerings
    Table 61. AstraZeneca Recent Development
    Table 62. Actelion Company Information
    Table 63. Actelion Introduction and Business Overview
    Table 64. Actelion Ischemic Heart Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 65. Actelion Ischemic Heart Disease Drugs Product Offerings
    Table 66. Actelion Recent Development
    Table 67. Bayer Company Information
    Table 68. Bayer Introduction and Business Overview
    Table 69. Bayer Ischemic Heart Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 70. Bayer Ischemic Heart Disease Drugs Product Offerings
    Table 71. Bayer Recent Development
    Table 72. Boehringer Ingelheim Company Information
    Table 73. Boehringer Ingelheim Introduction and Business Overview
    Table 74. Boehringer Ingelheim Ischemic Heart Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 75. Boehringer Ingelheim Ischemic Heart Disease Drugs Product Offerings
    Table 76. Boehringer Ingelheim Recent Development
    Table 77. Bristol-Myers Squibb Company Information
    Table 78. Bristol-Myers Squibb Introduction and Business Overview
    Table 79. Bristol-Myers Squibb Ischemic Heart Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 80. Bristol-Myers Squibb Ischemic Heart Disease Drugs Product Offerings
    Table 81. Bristol-Myers Squibb Recent Development
    Table 82. Baxter Company Information
    Table 83. Baxter Introduction and Business Overview
    Table 84. Baxter Ischemic Heart Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 85. Baxter Ischemic Heart Disease Drugs Product Offerings
    Table 86. Baxter Recent Development
    Table 87. Eli Lilly and Company Company Information
    Table 88. Eli Lilly and Company Introduction and Business Overview
    Table 89. Eli Lilly and Company Ischemic Heart Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 90. Eli Lilly and Company Ischemic Heart Disease Drugs Product Offerings
    Table 91. Eli Lilly and Company Recent Development
    Table 92. Novartis Company Information
    Table 93. Novartis Introduction and Business Overview
    Table 94. Novartis Ischemic Heart Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 95. Novartis Ischemic Heart Disease Drugs Product Offerings
    Table 96. Novartis Recent Development
    Table 97. Pfizer Company Information
    Table 98. Pfizer Introduction and Business Overview
    Table 99. Pfizer Ischemic Heart Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 100. Pfizer Ischemic Heart Disease Drugs Product Offerings
    Table 101. Pfizer Recent Development
    Table 102. Sanofi Company Information
    Table 103. Sanofi Introduction and Business Overview
    Table 104. Sanofi Ischemic Heart Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 105. Sanofi Ischemic Heart Disease Drugs Product Offerings
    Table 106. Sanofi Recent Development
    Table 107. Key Raw Materials Lists
    Table 108. Raw Materials Key Suppliers Lists
    Table 109. Ischemic Heart Disease Drugs Downstream Customers
    Table 110. Ischemic Heart Disease Drugs Distributors List
    Table 111. Research Programs/Design for This Report
    Table 112. Key Data Information from Secondary Sources
    Table 113. Key Data Information from Primary Sources
List of Figures
    Figure 1. Ischemic Heart Disease Drugs Product Picture
    Figure 2. Global Ischemic Heart Disease Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Ischemic Heart Disease Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 4. Global Ischemic Heart Disease Drugs Sales Volume (2019-2030) & (K Units)
    Figure 5. Global Ischemic Heart Disease Drugs Sales Price (2019-2030) & (USD/Unit)
    Figure 6. Ischemic Heart Disease Drugs Report Years Considered
    Figure 7. Global Ischemic Heart Disease Drugs Players Revenue Ranking (2023) & (US$ Million)
    Figure 8. Global Ischemic Heart Disease Drugs Players Sales Volume Ranking (2023) & (K Units)
    Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Ischemic Heart Disease Drugs Revenue in 2023
    Figure 10. Ischemic Heart Disease Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 11. Angina Pectoris Picture
    Figure 12. Myocardial Infarction Picture
    Figure 13. Global Ischemic Heart Disease Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 14. Global Ischemic Heart Disease Drugs Sales Value Market Share by Type, 2023 & 2030
    Figure 15. Global Ischemic Heart Disease Drugs Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
    Figure 16. Global Ischemic Heart Disease Drugs Sales Volume Market Share by Type, 2023 & 2030
    Figure 17. Global Ischemic Heart Disease Drugs Price by Type (2019-2030) & (USD/Unit)
    Figure 18. Product Picture of Anti-dyslipidemic Drugs
    Figure 19. Product Picture of Calcium Channel Blockers
    Figure 20. Product Picture of Beta-blockers
    Figure 21. Product Picture of ACE Inhibitors
    Figure 22. Product Picture of ARBs
    Figure 23. Product Picture of Vasodilators
    Figure 24. Product Picture of Antithrombotic Agents
    Figure 25. Global Ischemic Heart Disease Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 26. Global Ischemic Heart Disease Drugs Sales Value Market Share by Application, 2023 & 2030
    Figure 27. Global Ischemic Heart Disease Drugs Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
    Figure 28. Global Ischemic Heart Disease Drugs Sales Volume Market Share by Application, 2023 & 2030
    Figure 29. Global Ischemic Heart Disease Drugs Price by Application (2019-2030) & (USD/Unit)
    Figure 30. North America Ischemic Heart Disease Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 31. North America Ischemic Heart Disease Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 32. Europe Ischemic Heart Disease Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 33. Europe Ischemic Heart Disease Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 34. Asia Pacific Ischemic Heart Disease Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 35. Asia Pacific Ischemic Heart Disease Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 36. South America Ischemic Heart Disease Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 37. South America Ischemic Heart Disease Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 38. Middle East & Africa Ischemic Heart Disease Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 39. Middle East & Africa Ischemic Heart Disease Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 40. Key Countries/Regions Ischemic Heart Disease Drugs Sales Value (%), (2019-2030)
    Figure 41. Key Countries/Regions Ischemic Heart Disease Drugs Sales Volume (%), (2019-2030)
    Figure 42. United States Ischemic Heart Disease Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 43. United States Ischemic Heart Disease Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 44. United States Ischemic Heart Disease Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 45. Europe Ischemic Heart Disease Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 46. Europe Ischemic Heart Disease Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 47. Europe Ischemic Heart Disease Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 48. China Ischemic Heart Disease Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 49. China Ischemic Heart Disease Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 50. China Ischemic Heart Disease Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 51. Japan Ischemic Heart Disease Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 52. Japan Ischemic Heart Disease Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 53. Japan Ischemic Heart Disease Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 54. South Korea Ischemic Heart Disease Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 55. South Korea Ischemic Heart Disease Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 56. South Korea Ischemic Heart Disease Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 57. Southeast Asia Ischemic Heart Disease Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 58. Southeast Asia Ischemic Heart Disease Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 59. Southeast Asia Ischemic Heart Disease Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 60. India Ischemic Heart Disease Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 61. India Ischemic Heart Disease Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 62. India Ischemic Heart Disease Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 63. Ischemic Heart Disease Drugs Industrial Chain
    Figure 64. Ischemic Heart Disease Drugs Manufacturing Cost Structure
    Figure 65. Channels of Distribution (Direct Sales, and Distribution)
    Figure 66. Bottom-up and Top-down Approaches for This Report
    Figure 67. Data Triangulation
    Figure 68. Key Executives Interviewed

Description

The global market for Ischemic Heart Disease Drugs was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Ischemic Heart Disease Drugs, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Ischemic Heart Disease Drugs by region & country, by Type, and by Application.

The Ischemic Heart Disease Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ischemic Heart Disease Drugs.

Market Segmentation